In 2024, Spanish pharma focused on stabilizing finances rather than expanding, with six major players seeing an 18% profit drop compared to 2023. While Faes Farma...
Economic growth must absolutely soar in 2024 to justify these valuation metrics. Or, the Fed must slash borrowing costs back towards ZIRP. But the latter scenario...